Biofrontera (BFRIW) Liabilities and Shareholders Equity (2020 - 2025)
Biofrontera has reported Liabilities and Shareholders Equity over the past 6 years, most recently at $28.6 million for Q4 2025.
- Quarterly results put Liabilities and Shareholders Equity at $28.6 million for Q4 2025, up 29.24% from a year ago — trailing twelve months through Dec 2025 was $80.7 million (down 6.98% YoY), and the annual figure for FY2025 was $28.6 million, up 29.24%.
- Liabilities and Shareholders Equity for Q4 2025 was $28.6 million at Biofrontera, up from $15.4 million in the prior quarter.
- Over the last five years, Liabilities and Shareholders Equity for BFRIW hit a ceiling of $55.1 million in Q3 2022 and a floor of $15.4 million in Q3 2021.
- Median Liabilities and Shareholders Equity over the past 5 years was $27.9 million (2023), compared with a mean of $32.3 million.
- Biggest five-year swings in Liabilities and Shareholders Equity: soared 258.6% in 2022 and later plummeted 45.71% in 2024.
- Biofrontera's Liabilities and Shareholders Equity stood at $53.2 million in 2021, then dropped by 4.39% to $50.9 million in 2022, then tumbled by 45.11% to $27.9 million in 2023, then fell by 20.88% to $22.1 million in 2024, then increased by 29.24% to $28.6 million in 2025.
- The last three reported values for Liabilities and Shareholders Equity were $28.6 million (Q4 2025), $15.4 million (Q3 2025), and $20.1 million (Q2 2025) per Business Quant data.